精华制药(002349) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥363,535,559.83, a decrease of 0.98% compared to ¥367,129,069.92 in the same period last year[5] - Net profit attributable to shareholders was ¥62,219,690.39, down 12.47% from ¥71,080,090.21 year-on-year[5] - Basic earnings per share decreased by 12.49% to ¥0.0764 from ¥0.0873 in the same period last year[5] - Net profit for the current period is 71,517,435.39, down from 81,983,042.72 in the previous period, indicating a decrease of about 12.96%[22] - Operating profit for the current period is 82,750,757.93, compared to 95,898,146.18 in the previous period, reflecting a decline of approximately 13.66%[21] - Basic and diluted earnings per share for the current period are both 0.0764, down from 0.0873 in the previous period, a decrease of about 12.96%[22] Cash Flow - The net cash flow from operating activities increased significantly by 99.23%, reaching ¥61,601,252.72 compared to ¥30,919,958.81 in the previous year[5] - Cash flow from operating activities for the current period is 61,601,252.72, significantly higher than 30,919,958.81 in the previous period, an increase of approximately 99.06%[24] - Cash flow from investing activities shows a net outflow of 86,899,490.42, worsening from a net outflow of 62,645,591.74 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,375,895,581.63, reflecting a 2.24% increase from ¥3,301,779,777.14 at the end of the previous year[5] - The total liabilities as of March 31, 2025, were CNY 345,045,648.86, slightly up from CNY 344,656,275.77 at the beginning of the period[18] - The company's cash and cash equivalents decreased to CNY 995,477,816.13 from CNY 1,013,590,836.03[16] - Accounts receivable increased to CNY 311,903,474.84 from CNY 290,830,862.09, reflecting a growth of approximately 7.5%[17] - Inventory levels rose to CNY 272,415,011.09 from CNY 270,345,771.69, indicating a slight increase[17] - The company's total equity increased to CNY 3,030,849,932.77 from CNY 2,957,123,501.37, showing a growth of approximately 2.5%[18] - The company reported a total of CNY 12,662,407.57 in contract liabilities, up from CNY 11,441,558.92[18] - The company’s short-term borrowings decreased to CNY 10,006,936.11 from CNY 10,426,936.11[18] - The company’s retained earnings increased to CNY 927,095,764.42 from CNY 864,876,074.03, reflecting a growth of approximately 7.2%[18] Income and Expenses - The company's investment income surged by 248.05%, amounting to ¥472,032.72 compared to ¥135,620.88 in the previous year[8] - The company reported a significant increase in other income, which rose by 3627.56% to ¥760,227.89 from ¥20,394.78 in the same period last year[8] - The company experienced a 40.77% decrease in construction in progress, totaling ¥31,726,810.54 compared to ¥53,569,031.43 at the end of the previous year[8] - The company's financial expenses decreased by 53.33%, amounting to -¥4,749,911.40 compared to -¥10,177,062.05 in the previous year[8] - The company reported a significant decrease in non-operating expenses, totaling 1,154.91, down by 97.74% compared to the previous year[9] - Tax refunds received dropped to 655.75, a decrease of 99.59%, primarily due to a lack of VAT refunds from subsidiaries[9] - The company distributed dividends and interest payments amounting to 56,750.00, a decrease of 72.70% compared to the previous year[9] - The company reported a decrease in research and development expenses to 10,499,381.03 from 17,109,278.74, a reduction of approximately 38.67%[21] - The company experienced a decrease in tax expenses to 11,992,395.52 from 13,884,386.95, a decline of about 13.66%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 101,218, with no preferred shareholders[11] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 34.39% of shares, totaling 279,994,660[11] - The company plans to grant 17.79 million restricted stocks, accounting for 2.19% of the total share capital at the time of the announcement[15] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[9]